SELLAS Life Sciences (SLS) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$0.07
- EPS estimate
- −$0.08
- EPS surprise
- +8.74%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Aug 12, 2025
SELLAS Life Sciences reported Q2 2025 results on August 12, 2025. It posted a loss of $0.07 per share, slightly narrower than the $0.08 loss expected, a beat of 8.74%. No revenue was reported and no revenue estimate was given. A year earlier, in Q2 2024, the loss was $0.13 per share, so the loss narrowed by about 46%.
Every quarter in the table is a loss, but they have shrunk. Full-year totals went from $2.13 per share in 2022 to $1.34 in 2023 and $0.50 in 2024, and the first half of 2025 added up to $0.14. The widest quarterly loss in the table was $1.05 in Q1 2022, and the narrowest was $0.06 in Q4 2024. Revenue appears in only three early quarters, the largest being $5.7 million in Q1 2021. The table skips Q4 2021. Of the 19 quarters with an estimate, SELLAS beat 9 times and missed 10 times, but it beat in each of the last five.
The table holds no results after Q2 2025. Past third-quarter reports came out between November 9 and November 14. The next report in the table will show whether the quarterly loss stays near $0.07 per share.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 12, 2025 | −$0.08 | −$0.07 | +8.74% | $0.00 | SEC |
| Q1 2025 | May 13, 2025 | −$0.11 | −$0.07 | +33.33% | $0.00 | SEC |
| Q4 2024 | Mar 20, 2025 | −$0.11 | −$0.06 | +43.77% | $0.00 | SEC |
| Q3 2024 | Nov 13, 2024 | −$0.13 | −$0.10 | +21.07% | $0.00 | SEC |
| Q2 2024 | Aug 13, 2024 | −$0.17 | −$0.13 | +24.99% | $0.00 | SEC |
| Q1 2024 | May 14, 2024 | −$0.16 | −$0.21 | −31.25% | $0.00 | SEC |
| Q4 2023 | Mar 28, 2024 | $0.09 | −$0.23 | −365.28% | $0.00 | SEC |
| Q3 2023 | Nov 9, 2023 | $0.02 | −$0.33 | −1985.71% | $0.00 | SEC |
| Q2 2023 | Aug 10, 2023 | −$0.36 | −$0.31 | +12.68% | $0.00 | SEC |
| Q1 2023 | May 11, 2023 | −$0.29 | −$0.47 | −62.07% | $0.00 | SEC |
| Q4 2022 | Mar 16, 2023 | −$0.32 | −$0.33 | −3.13% | $0.00 | SEC |
| Q3 2022 | Nov 14, 2022 | −$0.39 | −$0.34 | +12.08% | $0.00 | SEC |
| Q2 2022 | Aug 11, 2022 | −$0.36 | −$0.41 | −12.85% | $0.00 | SEC |
| Q1 2022 | May 12, 2022 | −$0.38 | −$1.05 | −176.32% | $1.0M | SEC |
| Q3 2021 | Nov 12, 2021 | −$0.36 | −$0.45 | −25.00% | $0.00 | SEC |
| Q2 2021 | Aug 12, 2021 | −$0.41 | −$0.30 | +25.93% | $1.9M | SEC |
| Q1 2021 | May 13, 2021 | −$0.18 | −$0.16 | +11.11% | $5.7M | SEC |
| Q4 2020 | Mar 23, 2021 | −$0.19 | −$0.43 | −126.32% | $0.00 | SEC |
| Q3 2020 | Nov 13, 2020 | −$0.27 | −$0.53 | −96.30% | $0.00 | SEC |
| Q2 2020 | Aug 13, 2020 | $0.00 | −$0.66 | +0.00% | $0.00 | SEC |
Quarterly revenue
Frequently asked questions
When did SELLAS Life Sciences (SLS) last report earnings?
SELLAS Life Sciences last reported on Aug 12, 2025, covering fiscal Q2 2025.
Did SLS beat earnings estimates?
Yes. SELLAS Life Sciences reported EPS of −$0.07 for Q2 2025 against a −$0.08 estimate — a 8.74% beat.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.